PTH-034 Hemospray may not reliably achieve hemostasis beyond 48 hours in acute upper gastrointestinal bleeding

S, Dixon; Tate, David J.; Przemioslo, Robert; Lockett, M

doi:10.1136/gutjnl-2015-309861.922

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GRAPHE-Registry showed a rebleeding rate of 26.7 % on Day 8 and 33.5 % on Day 30 15 . Another study from Yau et al also revealed a rebleeding rate of 39 % within 7 days in 19 patients with UGIB 2 , meanwhile Dixon et al reported a 33 % rate of rebleeding within 30 days in patients with UGIB 16 . Despite no directly comparable report, our results with a rebleeding rate of 49 % within 7 days are grossly comparable to the literature.…”

Section: Discussionmentioning

confidence: 95%

Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience

et al. 2017

View full text Add to dashboard Cite

Background and study aims TC-325 (Hemospray, Cook Medical) is a powder agent for endoscopic hemostasis in patients with upper gastrointestinal bleeding (UGIB). Although most publications are based on case-reports and retrospective studies, data on efficacy are promising. Here we report our experience with TC-325 for diffuse or refractory UGIB. Patients and methods Data on patients receiving TC-325 for endoscopic hemostasis from November 2013 to February 2017 at our center were analyzed retrospectively. Primary endpoints were technical success (successful immediate hemostasis) and clinical success (effective hemostasis and no recurrent bleeding). Secondary endpoints were recurrent bleeding within 3 and 7 days, hospital mortality and TC-325 associated complications. TC-325 was used for bleeding not amenable to standard endoscopic treatment (e. g. diffuse bleeding) or as salvage therapy after failure of conventional methods Results Fifty-two patients received TC-325 treatment. Most of the patients were treated for peptic ulcer bleeding (18/52 patients, 34.6 %) and post-interventional bleeding (13/52 patients, 25 %). Hemospray was used in 23/52 (44.2 %) patients as monotherapy and in 29/52 (55.8 %) patients as a salvage therapy. Application of the powder on the bleeding source was successful in all patients with no therapy-related adverse events (AEs). Immediate hemostasis was achieved in 51/52 (98.1 %) patients. Recurrent bleeding within 3 and 7 days was observed in 22/51 and 25/51 patients respectively (43.1 % and 49 %). The overall clinical success was 56.9 % on day 3 and 51 % on day 7. Total mortality was 15.4 % (8 patients), bleeding associated mortality was 3.8 % (2 patients). There were no therapy-related AEs. Conclusions TC-325 showed a high technical success rate as monotherapy for bleeding sources not amenable to standard methods or as an “add-on” therapy after unsuccessful hemostasis. However, rebleeding was frequent in this cohort and further studies are warranted to exactly define a treatment algorithm for TC-325 use.

show abstract

Section: Discussionmentioning

confidence: 95%

Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience

et al. 2017

View full text Add to dashboard Cite

show abstract

“…GI bleeding pathologies are noted in Table 2. The median (range) Sheffield GI bleeding score was 12 (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Group 1 received haemostatic spray application as primary treatment.…”

Section: Resultsmentioning

confidence: 99%

“…This equates to our patient group in whom there was a 18% rebleeding rate, although only a 6% failure after reapplication. However, in a subsequent case series, the rate of rebleeding with haemostatic spray monotherapy was considerable prompting authors to recommend either a second relook or prolonged hospital observation (14). This was not the observation in our study in which hospital stay was comparable between the 2 approaches.…”

Section: Discussionmentioning

confidence: 99%

The Use and Safety of a Novel Haemostatic Spray in the Endoscopic Management of Acute Nonvariceal Upper Gastrointestinal Bleeding in Children

Thomson

Urs

Narula

et al. 2018

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…However, in a subsequent case series, the rate of rebleeding with hemostatic spray monotherapy was considerable prompting authors to recommend either a second re-look or prolonged hospital observation. 23 This raises the question as to whether hemostatic spray as monotherapy is a cost-effective approach. This was addressed in a recent study, which showed that the combination of hemostatic spray with conventional hemostatic measures was more cost-effective than hemostatic spray as monotherapy.…”

Section: Discussionmentioning

confidence: 99%

The use of hemostatic spray as an adjunct to conventional hemostatic measures in high-risk nonvariceal upper GI bleeding (with video)

Sinha

Lockman

Church

et al. 2016

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

show abstract

PTH-034 Hemospray may not reliably achieve hemostasis beyond 48 hours in acute upper gastrointestinal bleeding

Cited by 4 publications

References 0 publications

Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience

Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience

The Use and Safety of a Novel Haemostatic Spray in the Endoscopic Management of Acute Nonvariceal Upper Gastrointestinal Bleeding in Children

The use of hemostatic spray as an adjunct to conventional hemostatic measures in high-risk nonvariceal upper GI bleeding (with video)

Contact Info

Product

Resources

About